Advent to sell generic drugmaker Zentiva to GTCR
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
Advent acquired Zentiva from Sanofi in 2018 and transformed the company into a highly successful standalone business
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery
Combined strength of two brands across 11 states to elevate patient care delivery and access to doctors
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Subscribe To Our Newsletter & Stay Updated